Introduction
Tissue damage, resulting from ischaemia, is a common causative factor in producing the pathological changes associated with clinical conditions such as stroke and occlusive heart disease. Our understanding of the precise mechanisms involved in eliciting ischaemia or the appropriate pharmacological intervention is far from complete. A limiting factor to our understanding of the condition is the availability of convenient and reliable animal models.
Approximately 80% of strokes are thromboembolic in origin (Mohr et al., 1978) , the remainder being due to cerebral haemorrhage. Several attempts have been made to develop suitable models of ischaemic stroke either by reducing blood oxygen supply to the whole animal or by ligating vessels to reduce the blood supply to the whole brain or selected areas of the brain. Models of global ischaemia (Levine & Klein, 1960 ; Levine & Sohn, 1969) are attractive due to their simplicity but bear little relation to the clinical condition, whereas models of focal ischaemia (Anthony et al., 1963; Sundt & Waltz, 1966; Bederson et al., 1986 ) require invasive surgery. The production of ischaemia by the injec-tion of microspheres (Hegedus et al., 1985) or homologous blood clots (Kaneko et al., 1985; Penar, 1987) reduces invasiveness, but at the expense of reproducibility of the size and location of the infarct created. Such models are useful for studying post-ischaemic events in brain tissue. However, they provide no information regarding the development of the thrombotic event(s) responsible for the ischaemia. This is thought to involve the interaction of blood elements such as platelets, fibrin and possibly neutrophils with the vessel wall.
We have recently described a model for investigating platelet function in the rabbit in vivo. In this system, platelet accumulation in the cranium can be induced by intracarotid administration of thrombin ). This response is not produced by intravenous injection of thrombin or by intracarotid injection of other platelet agonists such as ADP, PAF or collagen ). The precise mechanism of this thrombin-induced platelet accumulation in the cranial vasculature remains to be determined. The present study has investigated the action of a PAF antagonist (BN 52021), a thrombin inhibitor (hirudin) and an inhibitor of NO synthase (L-NG-nitroarginine methyl ester, L-NAME) on thrombininduced platelet accumulation in order to ascertain the involvement of endogenously generated PAF, NO and thrombin in these processes. Furthermore, we have investigated the ability of various fibrinolytic drugs to reverse the established thrombosis in order to elucidate the role of generated fibrin in these thrombotic events. ' 2Author for correspondence. '." Macmillan Press Ltd, 1992 
Methods

Experimental animals
The study was carried out on rabbits (New Zealand White, Froxfield, Petersfield, Hampshire, U.K.) of either sex weighing 2.5 to 3.5 kg. Animals received a standard diet and water ad libitum.
Preparation of animals
The rabbits were anaesthetized with a combination of diazepam (5 mg kg-', i.p.) followed 10 min later by fentanyl citrate 0.315 mg ml-' and fluanisone 10 mg ml-' (Hypnorm, 0.4 ml kg-', i.m.). Anaesthesia was maintained by i.m. injections of Hypnorm (0.1 ml kg-') as necessary (approximately 30 min intervals). The left common carotid artery was cannulated in the direction of blood flow for the administration of thrombin and drugs. Intravenous administrations were made into a marginal ear vein.
"'Indium-labelling ofplatelets Full details of the protocol for isolation and radiolabelling of rabbit platelets have been described elsewhere Thiemermann et al., 1990) . Briefly, blood (9 ml) obtained from a marginal ear vein was collected into 1 ml of 3.8% (w/v) trisodium citrate and centrifuged (200 g, 10 min) to obtain platelet-rich plasma (PRP). The platelets were then washed by centrifugation (640 g, 15 min) in a calcium-free Tyrode solution containing prostaglandin El (PGE,, 300 ng ml-') (CFTP). After removal of the supernatant, the surface of the platelet pellet was carefully rinsed with 1 ml CFTP. The platelets were gently resuspended in 1 ml of CFTP and incubated for 1.5 min at 37°C with "'indium oxine (25-50 pCi). After a further centrifugation (640 g, 15 min) to remove any excess, unbound "'indium, the platelet pellet was resuspended in CFTP (1 ml/recipient rabbit). The labelled platelets were administered to anaesthetized recipient rabbits via a marginal ear vein.
'25Iodine-labelledfibrinogen '25Iodine-labelled human fibrinogen, purchased from Amersham International plc., was reconstituted in sterile saline; 100 pCi of label was injected intravenously into each recipient animal.
Monitoring of radiolabelled blood elements within the circulation Radioactivity associated with "'indium-labelled platelets or '251I-labelled human fibrinogen was continuously monitored by means of one inch crystal scintillation detectors placed over the thorax (to measure changes in the pulmonary circulation) and head (to measure changes in the cerebral circulation). Counts were estimated with a multi-channel spectrometer (Nuclear Enterprises NE 461) and logged with the aid of a special application interface (AIMS 8000, Mumed Ltd.) by a microcomputer (Dell System 200).
Responses to intracarotid administration of thrombin were measured as changes in radioactivity from baseline values and expressed as % increase in counts. The area under the curve of the agonist-induced % increase in counts was then calculated by computer-assisted planimetry, to give a measure of the response over the monitored time course.
Pharmacological modulation of cerebral thromboembolism
Animals were prepared for experimentation as described above. Radiolabelled platelets or fibrinogen, administered in a volume of 1 ml into a marginal ear vein, were allowed to equilibrate with the endogenous blood elements for at least 1 h.
Each animal received a bolus dose of adenosine diphosphate (ADP, 100 fLg kg-', i.c.) in order to determine whether the platelets were functioning normally and also to eliminate any platelets that might have been damaged during the labelling procedure . After a further 30 min, a bolus dose of thrombin (100 iu kg-', i.c.) was administered, except for the experiments with D-and L-NAME where 10 iu kg-' was given (to assess possible potentiation). The response to the bolus dose of thrombin was then monitored continuously for 3-6 h, according to the investigation being carried out. Separate groups of animals were used for each drug treatment and for controls. All controls received either saline or vehicle administration in identical fashion to the treated groups.
A variety of pharmacological agents were studied:
Recombinant desulphatohirudin (CGP 39393) CGP 39393 (specific activity 11,600 anti-thrombin units mg-') was prepared in saline and administered as a bolus dose of 1 mg kg-' i.c. to animals with ll'indium-labelled platelets. One group (n = 3) was pretreated with CGP 39393 1 min before the administration of thrombin while second and third groups received the CGP 39393 1 (n = 5) and 20 (n = 7) min, respectively, after the administration of thrombin.
BN 52021
BN 52021 was prepared in the supplied vehicle and administered as a bolus dose of 10 mg kg-' i.v. to animals with "'indium-labelled platelets 5 min before the intracarotid injection of thrombin.
Urokinase
Urokinase (from human kidney cells) was prepared in saline and administered as an infusion (20 i.u., i.c.) to animals with "'indium-labelled platelets. The infusion was started 20 min after the administration of thrombin and was continued for 45 min at a rate of 0.1 ml min-'. APSAC APSAC (batch number 046, manufactured 9/2/88) was prepared in saline and administered as a bolus dose of 200 tLg kg-' i.v. Since deacylation of this compound begins immediately upon reconstitution (Smith et al., 1982) , the drug was reconstituted not more than 10 min before injection.
In animals with "'indium-labelled platelets, APSAC was administered 20 min or 3 h after thrombin administration.
In another group of animals with circulating '251-fibrinogen, APSAC was administered 20 min after intracarotid thrombin administration.
L and D-NG-nitroarginine methyl ester L-NAME and D-NAME were prepared in saline. Separate groups of animals with circulating "'In-labelled platelets received a bolus dose of 100 mg kg-', i.c., of each substance.
The injections were made 5 min before injection of thrombin (l0iukg-1, i.c.).
Recombinant tissue-plasminogen activator (rt-PA)
Lyophilised rt-PA prepared in Chinese hamster ovary cells was dissolved in sterile saline. Animals with circulating "'Inplatelets were treated with rt-PA 20min after injection of thrombin (100 iu kg-', i.c.). Each animal received a bolus injection of 100 ftg kg-', i.c. followed by an intracarotid infusion of 20 pg kg-' min-' for 45 min, at a rate of 0.06 ml min-'.
Defibrotide
Defibrotide was prepared in sterile saline. One group of animals received a bolus dose of 32 mg kg-', i.c., followed by an intracarotid infusion of 32 mg kg-' h-' for 45 min. A second group was treated in a similar fashion with a higher dose of 64 mg kg-', i.c., bolus plus 64 mg kg-'h-' intracarotid infusion for 45 min. All treatments were begun 20 min after injection of thrombin (100 iu kg-', i.c.). The infusion rate was 0.06 ml min-'.
Drugs
Drugs used in this study were obtained from the following sources: diazepam (Valium) (Roche, Welwyn Garden City);
Hypnorm (Janssen Pharmaceuticals); thrombin, L-NAME, 
Results
Recombinant desulphatohirudin
Pretreatment of animals with the thrombin inhibitor CGP 39393 (1 mg kg-', i.c.) 1 min prior to thrombin 100 iu kg-', i.c., completely abolished the accumulation of radiolabelled platelets in the cranial vasculature ( Figure la) . Treatment of the rabbits with the same dose (1 mg kg-', i.c.) 1 min ( Figure   la ) or 20 min ( Figure Ib) after thrombin administration produced smaller but significant (P <0.05) reductions (41 and 35% respectively) in the accumulation of plateletassociated radioactivity seen in response to thrombin.
BN 52021
Pretreatment of the rabbits with the PAF antagonist BN 52021 (10 mg kg-', i.v.) 5 min before the administration of thrombin (100iukg-', i.c.) had no significant effect on the accumulation of radiolabelled platelets in the cranial vasculature (Table 1) .
Fibrinolytic agents
Administration of the fibrinolytic agents urokinase (20 u, i.c. infusion) (Figure 2a tion of thrombin was found to reverse significantly (P<0.05, Mann Whitney U test) the accumulation of fibrin(ogen) associated radioactivity in the cranial vasculature ( Figure 3b ). When administered 3 h after the initiation of the cerebral thromboembolism induced by thrombin, APSAC failed to produce a significant reversal of the accumulation of radiolabelled platelets (Figure 3c ).
Defibrotide
Addition of defibrotide (32mgkg-' bolus plus 32mgkg-' h-', i.c., infusion or 64mgkg-' bolus plus 64mg kg-' h-', i.c., infusion) did not alter significantly the ability of intracartid thrombin to induce platelet accumulation in the cerebral vasculature (Table 1) . There was a tendency for the maximal response to thrombin, at 30 min, to be reduced following treatment with the highest dose of defibrotide, but this did not achieve statistical significance (Table 1) .
L and D-NG-nitroarginine methyl ester
Intracarotid administration of L-NAME (100 mg kg-') or D-NAME (100 mg kg-') 5 min prior to thrombin failed to alter significantly the magnitude or duration of thrombininduced platelet accumulation within the cranial vasculature (Table 1) . Results expressed as mean ± s.e.mean percentage increase (above baseline) in "'indium counts in the head.
*DEF = defibrotide. Dose shown is bolus dose which was followed by an i.c. infusion of the same dose in mg kg-' h-' for 45 min.
Discussion
Intracarotid thrombin induces a marked, sustained accumulation of labelled fibrin(ogen) and platelets within the cerebral vasculature. The precise nature of the platelet accumulation is not known. It is not likely to be due to simple passive trapping of platelet aggregates since, if this were the case, it would be expected that other platelet agonists such as ADP, collagen and PAF would produce the same effect .
Thrombin has two main functions that are important in thrombosis, the conversion of fibrinogen into fibrin and the stimulation of platelet aggregation. It is becoming clear that thrombin plays a central role in thrombotic events (see Hemker & Beguin, 1986) , being potent with respect to platelet aggregation and secretion in comparison to other endogenous platelet agonists. Thrombin is also capable of amplifying its own production through the activation of Factors V and VIII (Nesheim & Mann, 1979) and by the expression of phospholipids at the platelet surface (Tracy,   0  30  60  90  120  150   1988 ). In addition, thrombin can limit its formation via the activation of Protein C. It is, therefore, possible that although the administration of thrombin into the carotid artery acts as a trigger for the subsequent platelet accumula-EIZII tion seen in the cerebral vasculature, there is also further thrombin generation which is important for the overall extent and duration of the observed platelet response. In order to investigate this, use was made of the potent and selective thrombin inhibitor, hirudin. Recombinant desulphatohirudin (CGP 39393) achieves thrombin inhibition by the formation of a stable non-covalent 1:1 complex with thrombin, the formation of which is independent of other plasma factors. It has been shown to have effective anticoagulant and antithrombotic properties not only in venous thrombosis models but also in extracorporeal shunt models and models of arterial thrombosis (Markwardt et al., 1982; Heras et al., 1989; Talbot et al., 1989) . It is, therefore, potentially useful ;; g Time (min) -a The present results demonstrate that CGP 39393 administered 1 min before i.c. thrombin completely abolished the response, indicating that the accumulation of platelet-assocrcentage change in cranial counts plotted against time in iated radioactivity in the cerebral vasculature was specifically k circulating "'In-labelled platelets. Thrombin (100iu initiated by thrombin. When CGP 39393 was administered 'as injected at time 0 in all animals. In (a), groups of after the intracarotid thrombin there was a reduced response, ived an i.c. infusion of saline (n = 5) (-) or urokinase suggesting that there was some thrombin generation follow-5) (-) over the time (45 min) dipicted by the bar. In (b), ingtetinig that thriwssome thrombin nimals received an i.c. bolus then infusion of saline ing the iontial administration. However, this thrombin or recombinant tissue plasminogen activator (rt-PA, generation is not likely to be solely responsible for the kg-', infusion 20 #g kg' min-') (n =4) (X) over the maintenance.of the response since the administration of CGP i) depicted by the bar. Values shown are mean with 39393 at 20 min was not capable of completely reversing the ticated by vertical bars. platelet accumulation. However, it is not known whether the thrombin generation results from prothroml formation on the activated platelet membrar factor expression at the vessel wall or to M CGP 39393 is able to gain access to the sil generation.
Thrombin is a potent stimulus to platelet a( addition it is known to elicit vascular wall 1983) and to release a variety of biologically from the vascular endothelium eg PAF an derived relaxing factor (EDRF) (Shuman, 15 duced in response to stimuli such as throi necessarily be released but may remain assoi endothelial cell (McIntyre et al., 1985; Lynch & Henson, 1986) and may even be expressed on the outer surface of the endothelial cell (Zimmerman et al., 1990) such that it may act as a signal to activate circulating blood cells (Kimani et al., 1988; Lamas et al., 1988; Zimmerman et al., 1990) and thus participate in the thrombin-induced platelet accumulation within the cerebral vasculature. However, the naturally occurring PAF receptor antagonist, BN 52021, at a dose which is known to be selective for PAF receptors in the rabbit (Hellewell & Williams, 1989; Coyle et al., 1989) , failed to inhibit the accumulation of radiolabelled platelets in the cerebral vasculature. These results suggest that the endogenous generation of PAF is not playing a role in initiating 2 or sustaining the platelet accumulation within the cerebral circulation induced by intracarotid thrombin. Endothelial cells are now recognised as being important 50 modulators of many aspects of haemostasis, including the activation of blood elements. One product of the vascular endothelium that may play a role in limiting platelet aggregation in vivo is EDRF or nitric oxide (NO). This mediator has been shown to be capable of inhibiting platelet adhesion (Radomski et al., 1987; Ignarro et al., 1988) and aggregation in vitro (Azuma et al., 1986; Alheid et al., 1987; Furlong et al., 1987; Bhardwaj et al., 1988) and also reducing platelet aggregation in vivo (Bhardwaj et al., 1988; Hogan et al., 1988) . Recently, inhibitors of NO biosynthesis from Larginine have been described, and one such inhibitor is L-NAME (Moore et al., 1990) . L-NAME has been shown to augment thrombin-induced platelet accumulation within the pulmonary vascular bed of the rabbit (May et al., 1991) , suggesting that NO may play a role in modulating the extent 150 of platelet aggregation induced by thrombin and the disaggregation of platelets and neutrophils within the pulmonary vasculature. However, L-NAME at a dose which produced a significant effect on pulmonary platelet accumulation induced by intravenous thrombin and at a 10 fold higher dose, failed to have any significant effect compared to the biologically inactive enantiomer, D-NAME. It would therefore seem that endogenous generation of NO is not important in modulating the cerebral platelet accumulation induced by intracarotid thrombin in the rabbit. ved an i.v. bolus The fibrinolytic agents used in this study were used as ,en streptokinase pharmacological tools to gain some insight into the imporn after thromblin tance of fibrin deposition in the response to intracarotid alon of salhne (a) thrombin. The use of fibrinolytic agents in thrombotic dis-l= 5, (b) n =4 or orders such as myocardial infarction and venous thrombosis is known to produce beneficial effects. The situation regarding the use of fibrinolytics in the management of stroke is less clear due to the dangers of haemorrhagic transformation of infarcted tissue both with respect to the optimal therabinase complex peutic regimen and degree of risk involved. An animal model ne or by tissue such as this may help to answer these questions. Administravhat extent the tion of APSAC 3 h after the intracarotid administration of te of thrombin thrombin did not appear to be effective in reversing the platelet accumulation, supporting previous studies (Reimer et ctivation but in al., 1977) that once the thrombus becomes established it is injury (Malik, more difficult to resolve. Defibrotide, another drug suggested active materials to have fibrinolytic activity failed to alter significantly the id endothelium duration of thrombin-induced platelet accumulation in the )86). PAF pro-cerebral vasculature. Nonetheless, this drug has been shown mbin may not to possess anti-ischaemic activity in a variety of organs ciated with the (Thiemermann et al., 1989) and so it will be of interest to determine whether this drug alters ischaemia resulting from thrombin-induced platelet embolisation within the cerebral circulation.
Intracarotid thrombin induces a marked, sustained accumulation of fibrin and platelets within the cerebral vasculature of the rabbit. The exact mechanisms by which this occurs are not clear but it is, initially, specifically mediated by thrombin and there appears to be some degree of ongoing thrombin generation as shown by the results with CGP 39393. Neither PAF nor NO seem to play a role in modulating this thrombin-induced platelet accumulation, as shown by a specific receptor antagonist and a specific biosynthesis inhibitor respectively. However, it is likely to represent a thrombotic event in which fibrin deposition plays an important role, as shown by the ability of fibrinolytic agents to reverse the accumulation of radiolabelled platelets. Care must be taken when comparing this to existing models of stroke since no formal evaluation of ischaemia or ischaemic tissue damage has been made. This is an aspect that warrants further investigation and this model has the potential to be of use in evaluating the effects of various thrombolytic agents and for investigating the interactions of platelets with the cerebral endothelium.
